Routine blood monitoring in acne vulgaris patients on isotretinoin: Is reassessment warranted? A retrospective cohort study from Tygerberg Hospital
DOI:
https://doi.org/10.7196/Keywords:
Acne vulgaris, Isotretinoin use, laboratory monitoring, blood result abnormalitiesAbstract
Background. Oral isotretinoin is an indispensable treatment for patients with resistant and severe acne vulgaris, both in South Africa (SA) and globally. While routine laboratory monitoring is often deemed unnecessary for young, healthy patients, it remains unclear whether this applies in the SA context.
Objectives. To assess the need for routine blood monitoring for acne vulgaris patients on isotretinoin treatment at Tygerberg Hospital, SA. Specifically, we wanted primarily to determine the prevalence of patients with acne vulgaris whose oral isotretinoin treatment was altered owing to blood result abnormalities, and secondarily, to determine the prevalence of adverse events and liver function and lipid profile abnormalities associated with isotretinoin.
Methods. This was a retrospective cohort study of hospital records from patients with acne vulgaris treated with oral isotretinoin at the dermatology clinic at Tygerberg Hospital between 1 January 2020 and 31 December 2023. There were 89 eligible records extracted from the Tygerberg Hospital Enterprise Content Management system. Baseline and 6-week follow-up laboratory data, including liver function tests and lipid profile, were extracted retrospectively from the National Health Laboratory Service.
Results. The sample comprised 89 patient hospital records, 62% male and 38% female. Of the total, 53% were aged between 12 and 20 years. Blood result abnormalities led to alterations in treatment regimens for 2/89 (2.2%) patients: one patient required treatment termination, while another continued on low-dose isotretinoin instead of the planned dose increase. Two patients (2.2%) developed increased aspartate aminotransferase levels and five (5.6%) developed new alanine aminotransferase increases above the upper limit of the normal range. Elevated triglyceride levels occurred in two patients (2.2%), and elevated cholesterol levels in nine (10.1%). Adverse events resulting in the premature termination of treatment with isotretinoin included one case of severe chest pain, one patient with pseudotumour cerebri and one patient who developed exuberant granulation tissue.
Conclusion. This single-centre retrospective review highlights the scarcity of blood result abnormalities due to isotretinoin in patients with acne vulgaris. There were only two patients (2.2%) who had their management altered owing to blood result abnormalities, and both had chronic conditions. This may suggest that routine monitoring is indicated in patients with comorbidities, but not in otherwise healthy young patients with acne. However, larger prospective studies are needed in SA before such conclusions can be drawn.
References
1. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2024;90(5):1006.e1-1006.e30. https://doi.org/10.1016/j.jaad.2023.12.017
2. Sinclair W, Jordaan HF, Global Alliance to Improve Outcomes in Acne. Acne guideline 2005 update. S Afr Med J 2005;95(11 Pt 2):881-892. pubmed.ncbi.nlm.nih.gov/16344888/ (accessed 14 April 2026).
3. Affleck A, Jackson D, Williams HC, Chavez P, Albrecht J. Is routine laboratory testing in healthy young patients taking isotretinoin necessary: A critically appraised topic. Br J Dermatol 2022;187(6
Suppl):S857-S865. https://doi.org/10.1111/bjd.21840
4. Lee YH, Scharnits TP, Muscat J, et al. Laboratory monitoring during isotretinoin therapy for acne:
A systematic review and meta-analysis. JAMA Dermatol 2016;152(1):35-44. https://doi.org/10.1001/
jamadermatol.2015.3091
5. Dlova NC, Chateau A, Khoza N, et al. Prevalence of skin diseases treated at public referral hospitals in KwaZulu-Natal, South Africa, 2018. Br J Dermatol 2018;178(1):e1-e2. https://doi.org/10.1111/ bjd.15534
6. Dlova NC, Mosam A, Tsoka-Gwegweni J. The spectrum and sequelae of acne in black South Africans seen in tertiary institutions. Skin Appendage Disord 2018;4(4):301-303. https://doi. org/10.1159/000488689
7. Strauss JS, Krowchuck DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56(4):651-663. https://doi.org/10.1016/j.jaad.2006.08.048
8. Harper JC. Acne vulgaris: What’s new in our 40th year. J Am Acad Dermatol 2020;82():526-527.
https://doi.org/10.1016/j.jaad.2019.01.092
9. Han JJ, Faletsky A, Barbieri JS, Mostaghimi A. New acne therapies and updates on use of spironolactone and isotretinoin: A narrative review. Dermatol Ther 2021;11(1):79-91. https://doi.org/10.1007/s13555- 020-00481-w
10. Dreno B, Bagatin E, Blume-Peytavi U, Rocha M, Gollnick H. Female type of adult acne: Physiological and psychological considerations and management. J Dtsch Dermatol Ges 2018;16(10):1185-1194. https://doi.org/10.1111/ddg.13664
11. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016;74(5):945-973. https://doi.org/10.1016/j.jaad.2015.12.037
12. Opel D, Kramer ON, Chevalier M, Bigby M, Albrecht J. Not every patient needs a triglyceride check, but all can get pancreatitis: A systematic review and clinical characterisation of isotretinoin-associated pancreatitis. Br J Dermatol 2017;177(4):960-966. https://doi.org/10.1111/bjd.15207
13. Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ. Isotretinoin therapy for acne vulgaris: A re-evaluation of the need for measurements of plasma lipids and liver function tests. Br J Dermatol 1993;129(6):704-707. https://doi.org/10.1111/j.1365-2133.1993.tb03336.x
14. Altman RS, Altman LJ, Altman JS. A proposed set of new guidelines for routine blood tests during isotretinoin therapy for acne vulgaris. Dermatology 2002;204(3):232-235. https://doi. org/10.1159/000057887
15. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. Arch Dermatol 2006;142(8):1016-1022. https://doi.org/10.1001/archderm.142.8.1016
16. Hansen TJ, Lucking SM, Miller JJ, et al. Standardised laboratory monitoring with use of isotretinoin in acne. J Am Acad Dermatol 2016;75(2):323-328. https://doi.org/10.1016/j.jaad.2016.03.019
17. Wolverton SE, Wu JJ. Comprehensive Dermatologic Drug Therapy. 4th ed. Amsterdam: Elsevier Health Sciences, 2019.
18. Demircay Z, Kus S, Sur H. Predictive factors for acne flare during isotretinoin treatment. Eur J Dermatol 2008;18(4):452-456. https://doi.org/10.1684/ejd.2008.0441
19. Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther 2017;30(4):e12483. https://doi.org/10.1111/dth.12483
20. Björnsson ES, Vucic V, Stirnimann G, Robles-Diaz M. Role of corticosteroids in drug-induced liver injury. A systematic review. Front Pharmacol 2022;10(13):820724. https://doi.org/10.3389/ fphar.2022.82072
21. Landis MN. Optimizing isotretinoin treatment of acne: Update on current recommendations for monitoring, dosing, safety, adverse effects, compliance, and outcomes. Am J Clin Dermatol 2020:21(3):411-419. https://doi.org/10.1007/s40257-020-00508-0
22. BagatinE,SousaCostaC.Theuseofisotretinoinforacne–anupdateonoptimaldosing,surveillance, and adverse effects. Expert Rev Clin Pharmacol 2020;3(8):885-897. https://doi.org/10.1080/1751243 3.2020.1796637
23. Sadeghzadeh-Bazargan A, Ghassemi M, Goodarzi A, et al. Systematic review of low-dose isotretinoin for treatment of acne vulgaris: Focus on indication, dosage, regimen, efficacy, safety, satisfaction, and follow up, based on clinical studies. Dermatol Ther 2020;34(1):e14438. https://doi.org/10.1111/ dth.14438
24. Samuels DV, Rosenthal R, Lin R, Chaudhari S, Natsuaki MN. Acne vulgaris and risk of depression and anxiety: A meta-analytic review. J Am Acad Dermatol 2020;83(2):532-541. https://doi.org/10.1016/j. jaad.2020.02.040
25. Sundstrom A, Alfredsson L, Sjolin-Forsberg G, et al. Association of suicide attempts with acne and treatment with isotretinoin: Retrospective Swedish cohort study. BMJ 2010;341:c5812-c5812. https:// doi.org/10.1136/bmj.c5812
26. Gradwohl K, Varghese M, Rosenblatt AE. Mood changes and clinical decision-making in adolescent patients on isotretinoin therapy for acne vulgaris. Pediatr Dermatol 2023;40(3):494-496. https://doi. org/10.1111/pde.15324
27. Angelette AL, Rando LL, Wadhwa RD, et al. Tetracycline-, doxycycline-, minocycline-induced pseudotumor cerebri and esophageal perforation. Adv Ther 2023;40(4):1366-1378. https://doi. org/10.1007/s12325-023-02435-y
28. Ang ERG, Zimmerman JCC, Malkin E. Pseudotumor cerebri secondary to minocycline intake. J Am Board Fam Pract 2002;15(3):229-233. pubmed.ncbi.nlm.nih.gov/12038730/ (accessed 17 April 2026). 29. Friedman DI. The pseudotumor cerebri syndrome. Neurol Clin 2024;42(2):433-471. https://doi.
org/10.1016/j.ncl.2024.02.001
Downloads
Published
Issue
Section
License
Copyright (c) 2026 J du Toit, N A Gray, T M Esterhuizen, W I Visser
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
